RAMP3 Enhances GLP-1-Mediated Insulin Secretion (Preprint)
This preprint (later published in JBC) shows RAMP3 modifies GLP-1 receptor signaling to enhance insulin secretion, suggesting a path to tissue-selective GLP-1 drugs.
Quick Facts
What This Study Found
RAMP3 interacts with the GLP-1 receptor, modifying its signaling profile and enhancing insulin secretion — findings later confirmed in the peer-reviewed publication.
Key Numbers
Same as RPEP-12215.
How They Did This
Cell-based laboratory study examining RAMP3-GLP-1 receptor interaction, signaling bias, and functional effects on insulin secretion (preprint version).
Why This Research Matters
Demonstrates that receptor accessory proteins can modify GLP-1 signaling in ways that could lead to safer, more targeted diabetes drugs.
The Bigger Picture
RAMPs could be the key to developing next-generation incretin drugs with improved tissue selectivity and reduced off-target effects.
What This Study Doesn't Tell Us
Preprint version — not yet peer-reviewed at time of posting. The peer-reviewed version was subsequently published in JBC (PMID 40835007).
Questions This Raises
- ?How does the final published version differ from this preprint?
- ?Can RAMP3-biased GLP-1 agonists be developed for clinical testing?
Trust & Context
- Key Stat:
- Preprint of peer-reviewed finding This bioRxiv preprint was subsequently published in the Journal of Biological Chemistry, confirming RAMP3 modification of GLP-1 signaling
- Evidence Grade:
- Preprint version of a study later peer-reviewed and published. The peer-reviewed version (PMID 40835007) represents the definitive record.
- Study Age:
- Posted as preprint in 2025, with the peer-reviewed version published in the Journal of Biological Chemistry the same year.
- Original Title:
- Receptor Activity-Modifying Protein 3 enhances GLP-1-mediated Insulin Secretion.
- Published In:
- bioRxiv : the preprint server for biology (2025)
- Authors:
- Pearce, Abigail(2), Kumari, Poonam(2), Sisk, Claudia M(2), Harris, Matthew, Yeung, Ho Yan, Winfield, Sabrina, Caron, Kathleen M, Ladds, Graham
- Database ID:
- RPEP-12996
Evidence Hierarchy
Frequently Asked Questions
Is this the same study as PMID 40835007?
Yes. This is the bioRxiv preprint version of the same research, which was subsequently peer-reviewed and published in the Journal of Biological Chemistry.
What did this study find about RAMP3 and GLP-1?
RAMP3 physically pairs with the GLP-1 receptor and shifts its signaling toward calcium pathways, enhancing insulin secretion. This could enable development of GLP-1 drugs that target specific tissues with fewer side effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12996APA
Pearce, Abigail; Kumari, Poonam; Sisk, Claudia M; Harris, Matthew; Yeung, Ho Yan; Winfield, Sabrina; Caron, Kathleen M; Ladds, Graham. (2025). Receptor Activity-Modifying Protein 3 enhances GLP-1-mediated Insulin Secretion.. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2025.01.24.634724
MLA
Pearce, Abigail, et al. "Receptor Activity-Modifying Protein 3 enhances GLP-1-mediated Insulin Secretion.." bioRxiv : the preprint server for biology, 2025. https://doi.org/10.1101/2025.01.24.634724
RethinkPeptides
RethinkPeptides Research Database. "Receptor Activity-Modifying Protein 3 enhances GLP-1-mediate..." RPEP-12996. Retrieved from https://rethinkpeptides.com/research/pearce-2025-receptor-activitymodifying-protein-3-2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.